GALNT5: A Potential Drug Target for Disabilities (G11227)

Target Name: GALNT5

NCBI ID: G11227

GALNT5

GALNT5: A Potential Drug Target for Disabilities

GALNT5 (GALNAC-T5) is a gene that encodes a protein known as GALNT5. GALNT5 is a member of the GALT family, which is a group of enzymes involved in the processing of glucose. The GALNT5 gene has been identified as a potential drug target or biomarker for several diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases.

The GALNT5 gene is located on chromosome 16 at position 218.2 and has a calculated p-value of 7.96e-15. The gene has 13 exons, and its protein product has a calculated molecular weight of 41.1 kDa. GALNT5 is expressed in many tissues and cells of the body, including the brain, pancreas, heart, and liver.

GALNT5 is involved in the processing of glucose, which is a primary source of energy for the body. In the body, glucose is converted into glucose-6-phosphate, which is then used as a substrate for the Enzyme Glucose-6-Phosphate Degradase (G6PD). G6PD is an enzyme that is responsible for breaking down glucose-6-phosphate, which is a key step in the metabolism of glucose.

GALNT5 has been shown to play a role in the regulation of glucose metabolism. Studies have shown that GALNT5 is involved in the regulation of cellular processes that are related to glucose metabolism, including the formation of glucose-6-phosphate, the breakdown of glucose-6-phosphate, and the regulation of insulin sensitivity.

In addition to its role in glucose metabolism, GALNT5 has also been shown to play a role in the regulation of cellular processes that are related to cell signaling. Studies have shown that GALNT5 is involved in the regulation of cellular processes that are related to cell signaling, including the formation of mitochondrial fusion proteins, the regulation of protein translation, and the regulation of DNA replication.

GALNT5 has also been shown to play a role in the development and progression of several diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases. Studies have shown that GALNT5 is involved in the regulation of cellular processes that are related to the development and progression of these diseases, including the regulation of cell proliferation, the formation of neurodegenerate structures, and the regulation of blood vessel formation.

GALNT5 has also been shown to play a role in the regulation of cellular processes that are related to pain perception and neurotransmission. Studies have shown that GALNT5 is involved in the regulation of cellular processes that are related to pain perception and neurotransmission, including the regulation of neurotransmitter release from pain-sensitive neurons and the regulation of pain modulation.

In conclusion, GALNT5 is a gene that encodes a protein that is involved in the processing of glucose and the regulation of cellular processes that are related to glucose metabolism, cell signaling, disease development and progression, and pain perception and neurotransmission. GALNT5 has been shown to play a role in the development and progression of several diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases. Therefore, GALNT5 is a potential drug target or biomarker for these diseases. Further research is needed to fully understand the role of GALNT5 in disease progression and to develop effective treatments.

Protein Name: Polypeptide N-acetylgalactosaminyltransferase 5

Functions: Catalyzes the initial reaction in O-linked oligosaccharide biosynthesis, the transfer of an N-acetyl-D-galactosamine residue to a serine or threonine residue on the protein receptor. Has activity toward EA2 peptide substrate, but has a weak activity toward Muc2 or Muc1b substrates (By similarity)

The "GALNT5 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GALNT5 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets